You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE backs Opdivo for head and neck cancer

The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS as a treatment for metastatic and recurrent head and neck cancer.